An observational study on immunohistochemical expression profile of PCNA in urothelial carcinoma of bladder and association with clinicopathological parameters

Authors

  • Srinivasan Raman
  • Muthu Sudalaimuthu
  • Kalaivani Amitkumar
  • Jaison Jacob John

Keywords:

PCNA, Urothelial carcinoma, Histopathology, Immunohistochemistry

Abstract

Background:

Bladder cancer remains as one of the most common cancers of the urinary tract, with higher rates of incidence and heterogenous molecular and histological components affecting its prognosis. Proliferating Cell Nuclear Antigen (PCNA) is a protein and immunohistochemical (IHC) biomarker associated with the G1/S phase of the cell cycle that is essential for the proliferation of neoplastic cells. This study aimed to describe the histomorphological aspects of UC of the bladder. To evaluate the expression of PCNA with clinicopathological parameters of the disease such as age, gender, clinical features, site, configuration, histological grade, stage, and lymphovascular invasion (LVI).

Materials and methods:

Forty histologically confirmed cases of urothelial carcinoma (UC) from the Department of Pathology at a tertiary care centre in South India were analyzed. PCNA immunohistochemistry was performed, assessing staining intensity and percentage of positive tumor cells. Chi-square tests evaluated associations with clinicopathological features such as age, gender, clinical presentation, tumor site, configuration, grade, type, stage, and LVI.

Results:

The expression of the PCNA was found to be significantly associated with sessile tumors (p=0.023), higher histological grading (p=0.001), advanced stage tumors (p < 0.001) and LVI (p = 0.036), suggesting possible association as a marker of tumor aggressiveness and progression. No associations were found with the parameters such as patient age, gender, clinical presentation, or location of the tumor concerning PCNA expression.

Conclusions:

Our study demonstrated PCNA overexpression in sessile, high-grade tumors, muscle-invasive tumors, LVI and with advanced tumor stage. This shows that PCNA may serve as a marker of proliferation and aggressiveness aiding in prognosis, treatment planning and decision making. More studies are required for validation of our findings

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

References

1. Dziewit A, Sinha AC. Cancer, Bladder. In: Essence of Anesthesia Practice E-Book. Elsevier; 2010. p. 62.

2. Leman AR, Noguchi E. The replication fork: Understanding the eukaryotic replication machinery and the challenges to genome duplication. Vol. 4, Genes. 2013. p. 1–32.

3. Zhou H, Huang T, Xiong Y, Peng L, Wang R, Jun Zhang G. The prognostic value of proliferating cell nuclear antigen expression in colorectal cancer: A meta-analysis. Vol. 97, Medicine (United States). Lippincott Williams and Wilkins; 2018.

4 WHO Classification of Tumours Editorial Board. Urinary and male genital tumours. 5th ed. Vol. 8. Lyon (France): IARC Press, 2022; p 131-169.

5. Yıldırım A, Kösem M, Sayar I, Gelincik I, Yavuz A, Bozkurt A, et al. Relationship of PCNA, C-erbB2 and CD44s expression with tumor grade and stage in urothelial carcinomas of the bladder. Int J Clin Exp Med. 2014; 7:1516–23.

6. Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024 May; 74:229–63.

7. Inagaki T, Ebisuno S, Uekado Y, Hirano A, Hiroi A, Shinka T, et al. PCNA and p53 in urinary bladder cancer: Correlation with histological findings and prognosis. International Journal of Urology. 1997; 4:172–7.

8. Shiina H, Igawa M, Nagami H, Yagi H, Urakami S, Yoneda T, et al. Immunohistochemical analysis of proliferating cell nuclear antigen, p53 protein and nm23 protein, and nuclear DNA content in transitional cell carcinoma of the bladder. Cancer. 1996 Oct; 78:1762–74.

9. Hattori K, Uchida K, Akaza H, Koiso K, Nemoto R, Harada M. Proliferating cell nuclear antigen cyclin in human transitional cell carcinoma. Br J Urol. 1995; 75:162–6.

10. Bozlu M, Orhan D, Baltaci S, Yaman Ö, Elhan AH, Tulunay Ö, et al. The prognostic value of proliferating cell nuclear antigen, Ki-67 and nucleolar organizer region in transitional cell carcinoma of the bladder. Int Urol Nephrol. 2002 Mar; 33:59–66.

11. Jaiswal M, Agarwal M, Pandey S, Fareed R. Her2neu expression in urinary bladder cancer: Histopathological, clinico-radiological and epidemiological aspects. Indian Journal of Pathology and Oncology. 2019 Aug; 6:489–96.

12. Helal NS, Omran Z, Moussa M. Assessment of survivin and p27 expression as potential prognostic markers in urothelial cell carcinoma of urinary bladder in Egyptian patients. African Journal of Urology. 2022 Dec;28.

13. Kumar S, Prajapati O, Vaiphei K, Parmar KM, Sriharsha AS, Singh SK. Human epidermal growth factor receptor 2/neu overexpression in urothelial carcinoma of the bladder and its prognostic significance: Is it worth hype? South Asian J Cancer. 2015 Jul; 4:115–7.

14. Bai X, He W, Yin H, Li X, Zhou X, Wei Z, et al. Prognostic significance of HER2 status evaluation using immunohistochemistry in patients with urothelial carcinoma of the bladder: A retrospective single center experience. Exp Ther Med. 2022 Nov; 24:704.

15. Miyake M, Gotoh D, Shimada K, Tatsumi Y, Nakai Y, Anai S, et al. Exploration of risk factors predicting outcomes for primary T1 high-grade bladder cancer and validation of the Spanish Urological Club for Oncological Treatment scoring model: Long-term follow-up experience at a single institute. International Journal of Urology. 2015 Jun; 22:541–7.

16. Brimo F, Wu C, Zeizafoun N, Tanguay S, Aprikian A, Mansure JJ, et al. Prognostic factors in T1 bladder urothelial carcinoma: The value of recording millimetric depth of invasion, diameter of invasive carcinoma, and muscularis mucosa invasion. Hum Pathol. 2013 Jan; 44:95–102.

Downloads

Published

2025-05-08

How to Cite

1.
Raman S, Sudalaimuthu M, Amitkumar K, John JJ. An observational study on immunohistochemical expression profile of PCNA in urothelial carcinoma of bladder and association with clinicopathological parameters. J Neonatal Surg [Internet]. 2025May8 [cited 2025Sep.21];14(21S):873-9. Available from: https://jneonatalsurg.com/index.php/jns/article/view/5391

Issue

Vol. 14 No. 21S (2025): Journal of Neonatal Surgery

Section

Original Article

License

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

You are free to:

  • Adapt — remix, transform, and build upon the material for any purpose, even commercially.

Terms:

  • Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
  • No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.